MAG3 Renal Scintigraphy & Upper Tract Nuclear Imaging
MAG3 complements anatomical imaging by assessing relative renal uptake and urinary drainage. Use this page for ordering and interpreting the functional study; use the CT urogram companion for anatomical planning and the UPJ obstruction article for disease-specific treatment decisions.
Quick Reference
| Finding or preparation issue | Practical interpretation |
|---|---|
| Prompt collecting-system washout, T½ <10 min | Strong evidence against obstruction in a technically adequate study |
| Prolonged T½, including >20 min | Does not establish obstruction or an indication for surgery by itself |
| Low split renal function (SRF) | Assess measurement quality, symptoms, anatomy, global renal reserve and trend; no universal nephrectomy cutoff |
| Adult furosemide | Usually 0.5 mg/kg or 40 mg IV; reduced renal function may require more, according to nuclear-medicine assessment |
| Bladder management | Void before acquisition; catheterize selectively when emptying is unreliable; include postvoid/gravity-assisted drainage assessment |
| CTU and MAG3 sequencing | Order according to the clinical question; no routine 48-hour delay for alleged contrast competition at MAG3 transporters |
The adult protocol and interpretation framework below is anchored to the SNMMI/EANM 2018 obstruction standard.[1]
1. Radiopharmaceutical: Tc-99m MAG3
Chemistry and Mechanism
Tc-99m mercaptoacetyltriglycine (MAG3) is predominantly cleared by proximal tubular secretion. Its relatively efficient extraction generally provides better kidney-to-background contrast than a filtration tracer such as DTPA when renal function is impaired. Severe dysfunction can still produce an indeterminate study; MAG3 does not make poor renal function irrelevant.[1]
A routine MAG3 split-function percentage is relative uptake, not a directly measured GFR. MAG3 clearance can be estimated with a validated camera- or plasma-based method, but that result should not be relabeled as GFR or treated as identical to effective renal plasma flow. The methods, normalization and reference values must be specified.[1][7]
2. The Renogram Curve: Three Phases
| Phase | What it contributes | Important limitation |
|---|---|---|
| Perfusion / early arrival | Tracer delivery and gross asymmetry | A perfusion curve alone does not diagnose a specific vascular lesion or transplant rejection |
| Uptake | Relative contribution of each kidney after background correction | Timing, depth, motion, injection infiltration and background activity can distort the percentage |
| Excretion / drainage | Parenchymal transit and collecting-system emptying, including response to diuresis | Retention can reflect obstruction, weak renal function, a large reservoir or poor bladder emptying |
Whole-kidney curves combine parenchymal and pelvic activity. Cortical and collecting-system regions of interest can help separate slow tissue transit from retained urine. A rising or plateau curve is a reason to examine these components, not a self-sufficient diagnosis of mechanical obstruction.[1]
3. Diuretic Renogram Protocol
Furosemide Timing Protocols
F0, F−15, F+20/F+30 and other established protocols are legitimate options. There is no universally preferred timing schedule. F0 is convenient and shorter; delayed furosemide permits observation of baseline drainage and lets tracer reach a dilated collecting system before testing washout. Very poor function may require delayed assessment rather than interpreting a rising early curve as obstruction. Consistency is valuable when comparing serial studies.[1]
The published 17-year MAG3-F0 experience also demonstrates that simultaneous administration is an established clinical protocol; it does not support calling F0 intrinsically inferior or unsuitable for measuring relative function. The correct uptake window remains important.[4]
Furosemide Dose and Hydration
- Adults: 0.5 mg/kg or 40 mg IV is the usual standard. 40 mg is not an absolute ceiling in renal impairment. A higher dose may be needed to obtain an adequate intratubular diuretic concentration; document the actual dose and whether an adequate urine response occurred.
- Hydration: unless fluid restriction or another contraindication applies, the adult standard suggests an additional oral fluid load of 5–10 mL/kg 30–60 minutes before the examination. Tailor route and volume to the patient; fasting and dehydration can compromise interpretation.
- Bladder: ask the patient to void before acquisition. Insert a freely draining catheter when anticipated voiding difficulty, a noncompliant bladder or diversion makes it necessary; routine catheterization of every adult is not required.[1]
Conditions That Confound Diuretic Renogram Interpretation
| Confounder | What to check |
|---|---|
| Dehydration or insufficient diuretic response | Preparation, renal function, dose and measured urine output |
| Severely reduced function | Whether enough tracer reached the collecting system to assess drainage reliably |
| Large compliant renal pelvis | Reservoir retention despite an unobstructed outlet; assess upright/postvoid emptying |
| Full bladder, reflux, urinary diversion | Emptying and drainage-catheter status; persistent reflux can distort washout |
| Injection infiltration, motion or inappropriate ROIs | Raw images and processing quality before accepting quantitative results |
| Diclofenac | Can delay ureteric transit; discuss withholding or repeating an abnormal study after discontinuation |
Postvoid/gravity-assisted images and residual activity can be more informative than T½ alone. An indeterminate examination should explain the limiting factor and how a repeat or complementary test could resolve it.[1]
T½ Interpretation
T½ describes a 50% fall in activity from the relevant maximum, using the laboratory's specified ROI and fitting method. It is not uniformly measured from the furosemide injection time, and results from different acquisition/processing methods are not interchangeable.[1]
| Result | Interpretation in context |
|---|---|
| <10 min | Prompt drainage generally excludes obstruction |
| 10–20 min | Requires the images, postvoid drainage, renal function and clinical context |
| >20 min or no measurable half-time | Concerning retention, but also possible with poor function, inadequate diuresis or a large reservoir; not an automatic intervention trigger |
4. Split Renal Function (SRF)
Calculation
SRF is the relative background-corrected uptake in each kidney, expressed as a fraction of the bilateral total. The uptake interval should precede substantial loss of tracer into the ureter/bladder; a later suitable interval may be needed with severely delayed uptake. Position, depth and background correction matter, particularly with ectopic kidneys and poor function.[1]
Right SRF = corrected right-kidney uptake /
(corrected right + corrected left uptake) × 100
The adult standard reports a 42–58% reference interval for relative MAG3 uptake using its specified integral/perirenal-background method. An outlying value identifies asymmetry, not a universal treatment threshold. A 50:50 split can coexist with severe bilateral dysfunction; relative percentages do not establish absolute renal reserve.[1]
Serial SRF Trending
Compare like with like: tracer, hydration, furosemide timing, positioning, uptake interval, ROI processing and drainage-device status. Consider whether an apparent change reflects true ipsilateral loss, altered contralateral function or measurement variation.
A prospective repeatability study in 24 men with stable renal function, scanned a mean of 11 days apart, found that a decline of 7 percentage points (for example 50% to 43%) exceeded expected variation under its protocol. This is a useful context-specific estimate, not a universal 5% change rule or a standalone operation threshold.[6]
Serum creatinine may remain stable despite unilateral deterioration because it reflects combined renal function. Use the relative study alongside global function and anatomical follow-up; do not infer a fixed percentage of ipsilateral loss from a normal creatinine.
5. Indications in Reconstructive Urology
Urethral Stricture — Upper Tract Surveillance
Order MAG3 when there is a specific unresolved functional or drainage question, such as persistent upper-tract dilation whose significance would change treatment. A urethral stricture, a high residual or planned urethroplasty alone does not establish a need for baseline and annual MAG3 scans. Ultrasound, renal function, symptoms and outlet evaluation often determine whether functional imaging adds value.
Neurogenic Bladder
MAG3 evaluates the upper tract; urodynamics evaluates storage pressure and compliance. A single 40 cm H₂O value is not a universal renogram-ordering rule across neurogenic diagnoses. Upper-tract surveillance should follow the patient's risk category, using renal imaging, renal-function assessment and urodynamic reassessment where indicated. The EAU neuro-urology guideline does not prescribe annual MAG3 for every neurogenic patient.[8]
For a poorly emptying/noncompliant bladder or a refluxing reservoir, agree on an appropriate drainage plan with nuclear medicine so bladder back-pressure does not confound the upper-tract study.[1]
Ureteral Reconstruction
MAG3 is particularly useful when split function or suspected impaired drainage will influence counseling, reconstruction planning or the evaluation of possible recurrence. It is not mandatory before every reimplantation, Boari flap or graft repair. Review the ureteral stricture hub for the clinical decision pathway.
After repair, select ultrasound, laboratory testing and functional imaging according to the procedure, baseline function, symptoms and unresolved concerns. Specify whether a stent or nephrostomy is present. A fixed schedule of MAG3 at 6–12 weeks, 6 months, 12 months and annually thereafter is not a universal standard.
Urinary Diversion Surveillance
Conduits, continent pouches and neobladders require ongoing renal and diversion follow-up. Lifelong follow-up is not synonymous with lifelong annual MAG3. Use renography when drainage or relative function needs clarification. Catheter drainage of a diversion/reservoir may be needed to reduce reflux and residual-urine confounding during the study.[1]
6. MAG3 vs. DTPA
| Feature | MAG3 | DTPA |
|---|---|---|
| Main renal handling | Tubular secretion | Glomerular filtration |
| Typical strength | Dynamic drainage and relative uptake, especially with impaired function | Filtration-based function measurement with a validated method |
| Poor renal function | Usually better kidney-to-background contrast; can still be indeterminate | Lower extraction can limit count statistics and drainage assessment |
| Meaning of a reported clearance | MAG3 clearance / tubular extraction measure | GFR-related measurement, subject to the acquisition and processing method |
Choose the tracer and measurement method with nuclear medicine. Avoid claiming that either tracer is interpretable only above a rigid GFR cutoff or that MAG3 is a direct GFR measurement.[1][7]
7. DMSA Renal Cortical Scintigraphy
DMSA provides static imaging of functioning renal cortex. Its role includes cortical defects/scarring, congenital renal anatomy and relative cortical contribution. It does not replace a diuretic drainage study. A cortical defect is nonspecific: acute inflammatory abnormalities and permanent scar must be distinguished through timing and context. The pediatric SNMMI/EANM standard advises delayed assessment, generally at least six months after acute infection, when the question is persistent scarring.[5]
Use DMSA selectively when cortical information changes the clinical decision. A scar alone does not decide whether antireflux repair or nephrectomy is appropriate. Renal-mass characterization and transplant assessment require their own diagnostic pathways rather than a generic DMSA-first rule.
8. Upper Tract Imaging Hierarchy
| Question | Useful test or combination |
|---|---|
| Is the collecting system dilated? | Ultrasound, interpreted with prior imaging and clinical context |
| Where is the anatomical lesion? | CTU, MRU or targeted retrograde/antegrade imaging as appropriate |
| Is drainage impaired and what is each kidney's relative contribution? | Dynamic renography with an appropriate diuretic protocol |
| Is there a cortical defect or scar? | DMSA when the result would affect management |
| Is reflux the question? | Cystographic evaluation; MAG3 is not the standard anatomical reflux test |
Retrograde Pyelogram (RGP) vs. MAG3
RGP defines luminal anatomy and can accompany endoscopic treatment. MAG3 assesses tracer handling and drainage. Neither alone answers every reconstructive question; combine the results with the history, cross-sectional imaging and laboratory assessment.
CT Urogram and MAG3 Sequencing
There is no routine requirement to wait 48 hours after iodinated CT contrast because of alleged competition with MAG3 at OAT transporters in the cited diuretic-renography standard. Choose sequence according to the question and local scheduling. Recent contrast remains relevant if accompanied by acute kidney injury, dehydration or another change in renal function; discuss those clinical issues with nuclear medicine rather than impose an unsupported fixed delay.[1]
9. Intervention Thresholds
Obstruction with Preserved Function
Prolonged drainage with preserved relative function does not automatically require surgery after one or two scans. Confirm that the study was adequate and integrate symptoms, infections, stones, anatomical progression, parenchymal transit and functional trend. Stable, asymptomatic dilation can justify observation; convincing clinically consequential obstruction can justify intervention without waiting for a preset number of scans.
Obstruction with Reduced Function
Low SRF increases the importance of sound interpretation and counseling. It does not prove irreversibility. Consider the patient's overall kidney reserve, duration and cause of obstruction, infection, pain, reconstructive feasibility and goals. A decompression trial can be useful in selected uncertain cases, but there is no universal nephrostomy-first algorithm or required recovery to 20% before reconstruction.
Very Low Relative Function
In a retrospective adult UPJO cohort with DRF ≤15%, 19 patients underwent pyeloplasty and 44 nephrectomy. Symptoms improved in both groups; mean DRF after pyeloplasty remained approximately 9.5% to 10%, without significant improvement. This supports selected organ preservation, not a promise of functional recovery or a claim of treatment equivalence: allocation was nonrandomized and follow-up was short.[3]
A low-functioning renal unit is therefore not automatically “nonfunctional,” and SRF <15% is not a universal nephrectomy indication. Conversely, reconstruction may not provide worthwhile benefit in every such kidney. Before nephrectomy, assess absolute/global and contralateral function; a contralateral percentage above 50% merely describes its relative share.
Functional Loss Without Obstruction
Investigate parenchymal disease, infection, vascular disease and changes in the opposite kidney as appropriate. Correlate with renal-function testing and anatomical imaging; involve nephrology when indicated. A normal drainage curve does not explain the cause of functional loss.
10. Special Protocols and Pearls
Renal Transplant Protocol
Allograft scintigraphy can contribute information about perfusion, function, leaks and drainage. Avoid diagnosing rejection versus acute tubular injury from a curve pattern alone. A biopsy-correlated study of 181 DTPA examinations in 127 recipients found considerable overlap between graft pathologies; this is DTPA evidence, not a validated MAG3-specific diagnostic rule. Coordinate the question with the transplant and nuclear-medicine teams, using Doppler, clinical assessment and biopsy when indicated.[9]
Pediatric Protocol Differences
Use a dedicated pediatric protocol, with weight-based administered activity and age-appropriate hydration. The SNMMI/EANM pediatric standard describes F0 and delayed F+20/F+30 protocols and furosemide 1 mg/kg IV, suggested maximum 40 mg. Routine catheterization is controversial; it is advised for selected conditions such as hydroureteronephrosis, posterior urethral valves, known reflux or neuropathic bladder. Sedation is rarely needed. Infant timing depends on the indication and clinical urgency.[2] The cited US mertiatide label establishes use from 30 days of age; safety/effectiveness below that age is not established. Earlier neonatal imaging therefore requires a specialist decision that accounts for off-label use and immature renal function.[10]
Post-Nephrostomy Tube Management
State the clinical question and agree on whether and when to clamp the nephrostomy before the scan. The report must record tube status. There is no universal “clamp two hours, then open after uptake” protocol: opening a tube during excretion can bypass the very obstruction being assessed. Do not ask a patient to manipulate or clamp a tube without the treating team's instructions.[1][2]
Drug Interactions
Provide a current medication list, including chronic diuretics and drugs that may affect renal handling or urinary transit. The adult standard suggests holding a chronic diuretic on the morning of the test to support hydration, with individual instructions from the treating team. Diclofenac can delay transit. Do not automatically stop ACE inhibitors or ARBs for routine obstruction renography; medication withholding for a separate ACE-inhibitor renography protocol is a different question. There is no general contrast-related 48-hour MAG3 prohibition.[1]
11. Ordering Checklist
- State the decision the scan should inform: drainage, relative contribution, suspected recurrence or response to treatment.
- Supply symptoms, relevant infections, recent creatinine/eGFR and prior imaging/scans.
- Describe surgery, anatomy, stents, nephrostomy tubes, diversion and anticipated voiding difficulty.
- Agree on hydration, medication instructions, bladder/reservoir drainage and any nephrostomy clamp plan.
- Ask for comparison with the prior study and identification of technical limitations.
12. Reporting Elements
Request the tracer/activity, furosemide dose and timing, preparation, patient position and drainage-device status. The interpretation should include relative uptake and processing method, qualitative transit/drainage, the definition of any reported T½, postvoid/gravity-assisted drainage, comparison with prior studies and an explicit explanation of indeterminate findings.[1][2]
Videos
References
1. Taylor AT, Brandon DC, de Palma D, et al. SNMMI Procedure Standard/EANM Practice Guideline for Diuretic Renal Scintigraphy in Adults With Suspected Upper Urinary Tract Obstruction 1.0. Semin Nucl Med. 2018;48(4):377–390. doi:10.1053/j.semnuclmed.2018.02.010. Full text.
2. Majd M, Bar-Sever Z, Santos AI, De Palma D. The SNMMI and EANM Procedural Guidelines for Diuresis Renography in Infants and Children. J Nucl Med. 2018;59(10):1636–1640. doi:10.2967/jnumed.118.215921.
3. Freitas PFS, Barbosa JABA, Cho DH, et al. Short-term outcomes of pyeloplasty vs. nephrectomy in adult patients with ureteropelvic junction obstruction and differential renal function ≤15%. Scand J Urol. 2021;55(3):192–196. doi:10.1080/21681805.2021.1879929.
4. Sfakianakis GN, Sfakianaki E, Georgiou M, et al. A renal protocol for all ages and all indications: mercapto-acetyl-triglycine (MAG3) with simultaneous injection of furosemide (MAG3-F0): a 17-year experience. Semin Nucl Med. 2009;39(3):156–173. doi:10.1053/j.semnuclmed.2008.11.001.
5. Vali R, Armstrong IS, Bar-Sever Z, et al. SNMMI procedure standard/EANM practice guideline on pediatric Tc-99m DMSA renal cortical scintigraphy: an update. Clin Transl Imaging. 2022. doi:10.1007/s40336-022-00484-x. Society guideline text.
6. Taylor A, Manatunga A, Halkar R, Issa MM, Shenvi NV. A 7% decrease in the differential renal uptake of MAG3 implies a loss in renal function. Urology. 2010;76(6):1512–1516. doi:10.1016/j.urology.2010.03.066.
7. Taylor A Jr, Corrigan PL, Galt J, et al. Measuring technetium-99m-MAG3 clearance with an improved camera-based method. J Nucl Med. 1995;36(9):1689–1695. PubMed.
8. European Association of Urology. EAU Guidelines on Neuro-urology. 2026. The guideline.
9. Gupta SK, Lewis G, Rogers KM, et al. Quantitative Tc-99m DTPA renal transplant scintigraphic parameters: assessment of interobserver agreement and correlation with graft pathologies. Am J Nucl Med Mol Imaging. 2014;4(3):213–224. PubMed.
10. Jubilant DraxImage Inc. Kit for the Preparation of Technetium Tc 99m Mertiatide Injection: US prescribing information. Revised January 2023. DailyMed label.